As the world's leading vaccine supplier, GSK will bring its vaccine field Three Musketeers hepatitis B vaccine Anzaishi, bivalent human papillomavirus (HPV) vaccine Xi Ruishi, and recombinant herpes zoster vaccine Xin anlishi to the 4th China International Import Expo, showing the concept of vaccine protection from infant to old age, covering the whole life cycle.
Among them, the recombinant herpes zoster vaccine Xinanlishi has won the Galen Prize, which is known as the "Nobel Prize of the Pharmaceutical Industry" three times, and was included in the first batch of 48 clinically urgent new drugs in the country in 2018, and was approved by the State Drug Administration of China in 2019 for the prevention of shingles in adults aged 50 and above. Since its launch in June 2020, Xin'anlishi has now made appointments for vaccination in nearly 250 cities across the country, covering more than 3,800 vaccination sites.
GSK has more than 100 years of history of scientific research and development of vaccines, with strong vaccine research and development strength and the world's leading patented adjuvant technology, has always been at the forefront of vaccine research and development. As one of the first batch of multinational pharmaceutical companies to enter China, gsk actively responds to the "14th Five-Year Plan and 2035 Long-term Goal Outline" to put the protection of people's health in a strategic position of priority development, adhere to the principle of prevention, help build a 'medical and prevention integration' health management system, and help Chinese people to do more, feel more comfortable and live longer.
Innovative adjuvant systems to improve vaccine protection
Adjuvant vaccines contain both antigens and adjuvants. Adjuvants enhance or modulate the vaccine immune response, producing a stronger and longer lasting immune response, especially for specific populations such as infants, the elderly, and immunocompromised populations, whose immune response can be improved. At the same time, the use of adjuvants is particularly important in the event of a pandemic, which can reduce the amount of antigen required for each dose of vaccine, which can produce more doses of vaccine, which has important implications for improving the global vaccine supply.
As a leader in innovative vaccines, GSK began to focus on the development of new adjuvant systems in the 1980s, which play a central role in vaccine innovation. Now, GSK applies advanced patented adjuvant systems to a wide range of vaccine products and collaborates more extensively around the world to support the development and production of innovative vaccine products by providing patented adjuvant systems.
Work together with all parties to build a healthy ecology of "medical and defense integration"
The "Opinions of the State Council on the Implementation of the Healthy China Action" proposes to adhere to the principle of prevention and put prevention in a more prominent position. Building a new healthy ecology of "integrating medical treatment and prevention" has become the consensus of all sectors of society.
All along, GSK has always kept in mind the commitment of "basing on China, working together with China, serving China", and is committed to bringing innovative products to Chinese patients and the public, and continuously expanding the vaccine portfolio. At the same time, GSK will continue to work with government agencies and other partners from all walks of life to disseminate the concept of vaccine protection throughout the life cycle, enhance the public's correct understanding of the value of vaccines, improve the accessibility of high-quality vaccine resources, and work together with all parties to build a 'medical and preventive integration' health ecosystem to help improve the overall health level of Chinese people."